InvestorsHub Logo
Followers 14
Posts 818
Boards Moderated 0
Alias Born 05/26/2014

Re: None

Sunday, 07/26/2020 10:54:49 AM

Sunday, July 26, 2020 10:54:49 AM

Post# of 448
Nabriva Therapeutics (NBRV) Catalysts
Merck collab: https://www.globenewswire.com/news-release/2020/07/15/2062852/0/en/Nabriva-Therapeutics-Enters-into-Exclusive-Agreement-to-Promote-and-Distribute-SIVEXTRO-tedizolid-phosphate-in-the-U-S.html Announced after hours yesterday
For comparison: Surface Oncology (SURF) announced a collaboration with Merck on May 20. Price hovered around $2.3 and jumped to a high of $7.66 at this time. That’s over 100% on this collaboration news alone with Merck. So plenty of upside left for NBRV
An EMA (Europe) approval for this same medicine (Lefamulin). Deadline this month. So news sometime this month.
Any positive news about their FDA approval for Contepo.